Clinical trials · Ohio
Myelofibrosis clinical trials in Ohio
We’re tracking 15 recruiting myelofibrosis studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Canton, OhioAges 18 years+ - NCT06343805RecruitingPhase 1
Study of AJ1-11095 for myelofibrosis after failed JAK2 inhibitor
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
Columbus, OhioAges 18 years+ - NCT07357727RecruitingPhase 3
Study of Pelabresib and Ruxolitinib for Myelofibrosis
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Columbus, OhioAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Cleveland, OhioAges 18 years+ - NCT06351631RecruitingPhase 3
Long-term safety study of bomedemstat for blood cancers
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Columbus, OhioAges 18 years+ - NCT06479135RecruitingPhase 3
Study of new drug added to ruxolitinib for myelofibrosis
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Cincinnati, OhioAges 18 years+ - NCT05280509RecruitingPhase 1/Phase 2
Test TL-895 plus ruxolitinib for myelofibrosis
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Cincinnati, OhioAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Columbus, OhioAges 18 years+ - NCT07623161RecruitingPhase 3
Elritercept versus placebo for myelofibrosis anemia on ruxolitinib
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Cleveland, OhioAges 18 years+ - NCT04176198RecruitingPhase 1/Phase 2
Oral nuvisertib for myelofibrosis after JAK inhibitor failure
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Columbus, OhioAges 18 years+ - NCT06773195RecruitingPhase 1/Phase 2
Study of Ruxolitinib and Ulixertinib for Myelofibrosis
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Cleveland, OhioAges 18 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Cleveland, OhioAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Cincinnati, OhioAges Any age - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Cleveland, OhioAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Cincinnati, OhioAges 13 years+
Myelofibrosis trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting myelofibrosis studies listed above.
- The Ohio State University Wexner Medical Center · 8 studies
- Cleveland Clinic · 6 studies
- Gabrail Cancer Center · 3 studies
- University of Cincinnati · 3 studies
- Cincinnati Children's Hospital Medical Center
- Cleveland Clinic Cancer Center Independence
- Cleveland Clinic Hillcrest Hospital Cancer Center
- Local Institution
What taking part in a myelofibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Myelofibrosis trials in other states
Common questions
- Are there myelofibrosis clinical trials in Ohio?
- Yes. We're currently tracking 15 recruiting myelofibrosis studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myelofibrosis study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myelofibrosis studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.